Aug 2026 (Q3 FY26) — Sep 24, 2026
H.B. Fuller Q3 FY26 — Strong Profitability and Quantum Leap Progress
Read the full callFuller H B earnings: last reported Thu, 24 Sep 2026, for the quarter ended Aug 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 938 | +5.2% YoY | Quarterly, as filed | Quarter to Aug 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Aug 2026 | Not in the filed figures for the quarter to aug 2026. No older figure is substituted. | ||
| Net profit | 79.2 | +17.9% YoY | Quarterly, as filed | Quarter to Aug 2026 | Profit after tax as filed. |
Price
1Y: $58.81 on 17 Oct 2025 → $51.06. High $67.49 (13 Feb 2026), low $49.29 (20 Mar 2026).
Overview
Call summaries
H.B. Fuller Q3 FY26 — Strong Profitability and Quantum Leap Progress
Read the full callH.B. Fuller Q2 FY26 — Pricing-led margin expansion and ~GBP715M AMS medical acquisition offer
Read the full callEvery analysed call
Financials
Net profit, year on year: +18% (quarter to aug 2026 against aug 2025).
| Line item | Nov 2024 | Mar 2025 | May 2025 | Aug 2025 | Nov 2025 | Feb 2026 | May 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 923 | 789 | 898 | 892 | 895 | 771 | 950 | 938 |
| Operating profit | 76 | 46 | 100 | 110 | — | — | — | — |
| Operating margin | 8.3% | 5.9% | 11.1% | 12.3% | — | — | — | — |
| Profit before tax | -1 | 19 | 73 | 83 | 41 | 28 | 92 | 101 |
| Tax rate | −1496.2% | 31.8% | 44.7% | 19.9% | 29.4% | 26.9% | 27.8% | 24.4% |
| Net profit | -7 | 13 | 42 | 67 | 30 | 21 | 68 | 79 |
| EPS ($ per share) | — | 0.24 | 0.77 | 1.23 | — | 0.38 | 1.25 | 1.46 |
| Line item | Dec 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Dec 2022 | Dec 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 51 | 51 | 52 | 53 | 54 | 54 | 55 | 54 |
| Reserves | 1,286 | 1,384 | 1,474 | 1,601 | 1,741 | 1,843 | 1,925 | 2,026 |
| Total liabilities | 3,023 | 2,763 | 2,655 | 2,677 | 2,853 | 2,968 | 3,103 | 3,180 |
| Fixed assets | 637 | 630 | 671 | 695 | 734 | 825 | 882 | 935 |
| Total assets | 4,176 | 3,986 | 4,037 | 4,275 | 4,464 | 4,724 | 4,933 | 5,183 |
| Line item | Dec 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Dec 2022 | Dec 2023 | Nov 2024 | Nov 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 253 | 269 | 332 | 213 | 257 | 378 | 302 | 263 |
| Cash from investing | -62 | 7 | -109 | -95 | -375 | -319 | -407 | -232 |
| Cash from financing | -229 | -315 | -239 | -154 | 160 | 35 | 112 | -108 |
| Net cash flow | -44 | -39 | -12 | -39 | 18 | 100 | -10 | -62 |
| Capital expenditure | -68 | -62 | -87 | -96 | -130 | -119 | -139 | -142 |
| Free cash flow | 185 | 207 | 244 | 117 | 127 | 259 | 163 | 121 |
117 filings between Oct 27, 2025 and Oct 7, 2026.
Purchases
$1.48M
12 purchases by 9 insiders
Sales
$1.86M
3 sales by 2 insiders
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Weaver Nathan D. | — | $1.01M | Aug 11, 2026 |
| Corkrean John J | — | $857.8K | Oct 27, 2025 |
| BAILLY R JEFFREY | $500.0K | — | Oct 7, 2026 |
| Mastin Celeste Beeks | $295.1K | — | Apr 7, 2026 |
| Rasmussen Trangsrud Teresa J | $165.8K | — | Sep 28, 2026 |
| FLORNESS DANIEL L | $100.2K | — | Sep 28, 2026 |
| Zaheer Srilata | $100.1K | — | Sep 29, 2026 |
| Lauber Charles T | $100.0K | — | Sep 29, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | BAILLY R JEFFREY Director | Purchase | 10,000 | $500.0K |
| Oct 4, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Award | 19 | $954 |
| Oct 4, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Tax withheld | 141 | $7.1K |
| Oct 4, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Option exercise | 453 | $22.7K |
| Oct 4, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Tax withheld | 61 | $3.1K |
| Oct 4, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Option exercise | 202 | $10.1K |
| Sep 30, 2026 | Martin Celine Christine Director | Purchase | 465 | $23.0K |
| Sep 29, 2026 | Happe Michael J Director | Purchase | 2,000 | $99.3K |
| Sep 29, 2026 | Zaheer Srilata Director | Purchase | 40 | $2.0K |
| Sep 29, 2026 | Lauber Charles T Director | Purchase | 2,005 | $100.0K |
| Sep 28, 2026 | Rasmussen Trangsrud Teresa J Director | Purchase | 1,542 | $75.5K |
| Sep 28, 2026 | Rasmussen Trangsrud Teresa J Director | Purchase | 500 | $24.5K |
| Sep 28, 2026 | HANDLEY THOMAS W Director | Purchase | 2,000 | $98.8K |
| Sep 28, 2026 | Zaheer Srilata Director | Purchase | 2,000 | $98.1K |
| Sep 28, 2026 | FLORNESS DANIEL L Director | Purchase | 2,030 | $100.2K |
| Aug 11, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Option exercise | 4,585 | $245.6K |
| Aug 11, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Option exercise | 4,976 | $249.3K |
| Aug 11, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Sale | 9,561 | $593.3K |
| Jul 9, 2026 | Magalhaes Joao Sr. VP, Engineering Adhesives | Option exercise | 1,658 | $83.1K |
| Apr 17, 2026 | Rasmussen Trangsrud Teresa J Director | Purchase | 1,000 | $65.8K |
| Apr 7, 2026 | Mastin Celeste Beeks President and CEO | Purchase | 5,170 | $295.1K |
| Feb 4, 2026 | Magalhaes Joao Sr. VP, Engineering Adhesives | Option exercise | 519 | $32.7K |
| Feb 4, 2026 | Magalhaes Joao Sr. VP, Engineering Adhesives | Tax withheld | 245 | $15.4K |
| Jan 27, 2026 | Du Xinyu Sr. VP, Global R&D | Tax withheld | 134 | $8.0K |
| Jan 27, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Tax withheld | 217 | $13.0K |
| Jan 27, 2026 | Corkrean John J Executive VP and CFO | Tax withheld | 442 | $26.4K |
| Jan 27, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Option exercise | 600 | $35.9K |
| Jan 27, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Option exercise | 870 | $52.0K |
| Jan 27, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Tax withheld | 268 | $16.0K |
| Jan 27, 2026 | East James J. Executive Vice President, HHC | Option exercise | 870 | $52.0K |
| Jan 27, 2026 | Mastin Celeste Beeks President and CEO | Tax withheld | 3,122 | $186.7K |
| Jan 27, 2026 | Campe Heather Sr. VP, International Growth | Option exercise | 634 | $37.9K |
| Jan 27, 2026 | Du Xinyu Sr. VP, Global R&D | Option exercise | 448 | $26.8K |
| Jan 27, 2026 | Martsching Robert J VP, Corporate Controller | Tax withheld | 77 | $4.6K |
| Jan 27, 2026 | Martsching Robert J VP, Corporate Controller | Option exercise | 269 | $16.1K |
| Jan 27, 2026 | Malik Muhammad Shahbaz Senior VP, BAS | Tax withheld | 192 | $11.5K |
| Jan 27, 2026 | Malik Muhammad Shahbaz Senior VP, BAS | Option exercise | 600 | $35.9K |
| Jan 27, 2026 | Lorenz Laura J Sr. VP, HR & Communication | Tax withheld | 367 | $22.0K |
| Jan 27, 2026 | Corkrean John J Executive VP and CFO | Option exercise | 1,441 | $86.2K |
| Jan 27, 2026 | Lorenz Laura J Sr. VP, HR & Communication | Tax withheld | 217 | $13.0K |
| Jan 27, 2026 | Lorenz Laura J Sr. VP, HR & Communication | Option exercise | 600 | $35.9K |
| Jan 27, 2026 | Campe Heather Sr. VP, International Growth | Tax withheld | 161 | $9.6K |
| Jan 27, 2026 | Lorenz Laura J Sr. VP, HR & Communication | Option exercise | 1,020 | $61.0K |
| Jan 27, 2026 | East James J. Executive Vice President, HHC | Tax withheld | 192 | $11.5K |
| Jan 27, 2026 | Mastin Celeste Beeks President and CEO | Option exercise | 7,933 | $474.5K |
| Jan 26, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Tax withheld | 192 | $11.5K |
| Jan 26, 2026 | Weaver Nathan D. Exec VP, Business Transform. | Option exercise | 555 | $33.3K |
| Jan 26, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Tax withheld | 183 | $11.0K |
| Jan 26, 2026 | Ogunsanya Gregory O. Sr. VP, GC and Corp Secretary | Option exercise | 506 | $30.4K |
| Jan 26, 2026 | Mastin Celeste Beeks President and CEO | Tax withheld | 2,303 | $138.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow FULLER H B CO and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading